These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 30610419

  • 21. Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29-34 wGA) infants without outpatient palivizumab administration.
    Packnett ER, Winer IH, Oladapo A, Wojdyla M.
    Hum Vaccin Immunother; 2023 Aug; 19(2):2252289. PubMed ID: 37828711
    [Abstract] [Full Text] [Related]

  • 22. Restricted Palivizumab Recommendations and the Impact on RSV Hospitalizations among Infants Born at > 29 Weeks of Gestational Age: An Italian Multicenter Study.
    Priante E, Tavella E, Girardi E, Militello MA, Mardegan V, Maule MM, Dall'Agnola A, Baraldi E, Manzoni P.
    Am J Perinatol; 2019 Jul; 36(S 02):S77-S82. PubMed ID: 31238365
    [Abstract] [Full Text] [Related]

  • 23. Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations.
    Paes B, Mitchell I, Li A, Lanctôt KL.
    Eur J Pediatr; 2012 May; 171(5):833-41. PubMed ID: 22203430
    [Abstract] [Full Text] [Related]

  • 24. Palivizumab Prophylaxis among Infants at Increased Risk of Hospitalization due to Respiratory Syncytial Virus Infection in UAE: A Hospital-Based Study.
    Elhalik M, El-Atawi K, Dash SK, Faquih A, Satyan AD, Gourshettiwar N, Khan A, Varughese S, Ramesh A, Khamis E.
    Can Respir J; 2019 May; 2019():2986286. PubMed ID: 31871513
    [Abstract] [Full Text] [Related]

  • 25. Six-monthly palivizumab prophylaxis effectively reduced RSV-associated hospitalization rates of preterm infants in a subtropical area: a population-based cohort study.
    Lin YJ, Chung CH, Chi H, Lin CH.
    Pediatr Res; 2019 Nov; 86(5):628-634. PubMed ID: 31261371
    [Abstract] [Full Text] [Related]

  • 26. The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States.
    Kong AM, Krilov LR, Fergie J, Goldstein M, Diakun D, Wade SW, Pavilack M, McLaurin KK.
    Am J Perinatol; 2018 Jan; 35(2):192-200. PubMed ID: 28881376
    [Abstract] [Full Text] [Related]

  • 27. A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29-35 weeks' gestational age.
    Keary IP, Ravasio R, Fullarton JR, Manzoni P, Lanari M, Paes BA, Carbonell-Estrany X, Baraldi E, Tarride JÉ, Rodgers-Gray B.
    PLoS One; 2023 Jan; 18(8):e0289828. PubMed ID: 37561741
    [Abstract] [Full Text] [Related]

  • 28. Real-World Studies of Respiratory Syncytial Virus Hospitalizations among Moderate/Late Preterm Infants Exposed to Passive Immunoprophylaxis with Palivizumab.
    Manzoni P, Baraldi E, Luna MS, Tzialla C.
    Am J Perinatol; 2022 Dec; 39(S 01):S7-S13. PubMed ID: 36307092
    [Abstract] [Full Text] [Related]

  • 29. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
    Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B.
    Cochrane Database Syst Rev; 2013 Apr 30; (4):CD006602. PubMed ID: 23633336
    [Abstract] [Full Text] [Related]

  • 30. Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis.
    Krilov LR, Masaquel AS, Weiner LB, Smith DM, Wade SW, Mahadevia PJ.
    BMC Pediatr; 2014 Oct 13; 14():261. PubMed ID: 25308481
    [Abstract] [Full Text] [Related]

  • 31. Palivizumab use in infants with Down syndrome-report from the German Synagis™ Registry 2009-2016.
    Simon A, Gehrmann S, Wagenpfeil G, Wagenpfeil S.
    Eur J Pediatr; 2018 Jun 13; 177(6):903-911. PubMed ID: 29651734
    [Abstract] [Full Text] [Related]

  • 32. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
    Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J, IRIS Study Group.
    Pediatr Infect Dis J; 2003 Sep 13; 22(9):823-7. PubMed ID: 14506376
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Pediatric intensive care unit admission due to respiratory syncytial virus: Retrospective multicenter study.
    Kang JM, Lee J, Kim YK, Cho HK, Park SE, Kim KH, Kim MJ, Kim S, Kim YJ.
    Pediatr Int; 2019 Jul 13; 61(7):688-696. PubMed ID: 31107995
    [Abstract] [Full Text] [Related]

  • 35. Impact of the 2014 American Academy of Pediatrics Immunoprophylaxis Policy on the Rate, Severity, and Cost of Respiratory Syncytial Virus Hospitalizations among Preterm Infants.
    Krilov LR, Fergie J, Goldstein M, Brannman L.
    Am J Perinatol; 2020 Jan 13; 37(2):174-183. PubMed ID: 31430818
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. One-year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America.
    Castillo LM, Bugarin G, Arias JC, Barajas Rangel JI, Serra ME, Vain N.
    J Pediatr (Rio J); 2017 Jan 13; 93(5):467-474. PubMed ID: 28236418
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.